NCT03533946View on ClinicalTrials.gov

Rucaparib in Nonmetastatic prOstAte With BRCAness

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 20, 2019

Primary Completion Date

January 12, 2023

Study Completion Date

January 12, 2023

Conditions
Prostate Cancer
Interventions
DRUG

Rucaparib

Treatment with rucaparib will begin on Cycle 1 Day 1 and continue at 600 mg twice daily. Therapy continues until Prostate Specific Antigen (PSA) progression or intolerable toxicities.

Trial Locations (1)

84112

Huntsman Cancer Institute, Salt Lake City

Sponsors

Collaborators (1)

Clovis Oncology, Inc.
All Listed Sponsors
collaborator

Clovis Oncology, Inc.

INDUSTRY

lead

University of Utah

OTHER

NCT03533946 - Rucaparib in Nonmetastatic prOstAte With BRCAness | Biotech Hunter | Biotech Hunter